According to Fosun Pharmaceutical's announcement, the company received a notice from Fosun Hi-Tech, the controlling shareholder, that it will pledge 330 million A-shares of the company on September 3, 2026. The pledge period is the Shanghai Changning Branch of the Industrial and Commercial Bank of China until September 8, 2028, accounting for 34.32% of its shares, accounting for 12.36% of the company's total share capital, and the use of capital is debt repayment. As of the closing of the market on September 3, 2026, Fosun Hi-Tech held 961 million shares of the company, accounting for 36.00% of the total share capital; after this pledge, it pledged a total of 696 million shares, accounting for 26.07% of the total share capital. Fosun Hi-Tech and its co-actors held a total of 968 million shares of the company, accounting for 36.24% of the total share capital; the cumulative pledged shares accounted for 71.94% of their holdings. This pledge will not result in a change in the company's actual control.

According to Fosun Pharmaceutical's announcement, the company received a notice from Fosun Hi-Tech, the controlling shareholder, that it will pledge 330 million A-shares of the company on September 3, 2026. The pledge period is the Shanghai Changning Branch of the Industrial and Commercial Bank of China until September 8, 2028, accounting for 34.32% of its shares, accounting for 12.36% of the company's total share capital, and the use of capital is debt repayment. As of the closing of the market on September 3, 2026, Fosun Hi-Tech held 961 million shares of the company, accounting for 36.00% of the total share capital; after this pledge, it pledged a total of 696 million shares, accounting for 26.07% of the total share capital. Fosun Hi-Tech and its co-actors held a total of 968 million shares of the company, accounting for 36.24% of the total share capital; the cumulative pledged shares accounted for 71.94% of their holdings. This pledge will not result in a change in the company's actual control.